Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy.

H E Skipper

    Cancer
    |March 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Chemotherapy trial results require adjustments for cancer staging, dose response, and tumor regrowth rates when comparing across different cancers. Integrating these factors improves trial planning and reveals drug resistance as a key cause of treatment failure.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Dose intensity versus total dose of chemotherapy: an experimental basis.

    Important advances in oncology·1990
    Same author

    Tumor differences, drug differences, treatment design differences, and effects on therapeutic outcome (degree and duration of therapeutic response).

    Progress in clinical and biological research·1990
    Same author

    Experimental adjuvant chemotherapy: an overview.

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·1986
    Same author

    On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).

    Bulletin of mathematical biology·1986
    Same author

    Laboratory models: some historical perspective.

    Cancer treatment reports·1986
    Same author

    Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy.

    Important advances in oncology·1985

    Area of Science:

    • Oncology
    • Cancer Research
    • Pharmacology

    Background:

    • Translating chemotherapy trial results between different cancer types (animal or human) is complex.
    • Differences in cancer staging, dose-response relationships, and tumor regrowth rates complicate direct comparisons.
    • Understanding these variables is crucial for effective experimental therapeutic trial design and interpretation.

    Purpose of the Study:

    • To illustrate the necessity of correcting for staging, dose response, and tumor regrowth rates when extrapolating chemotherapy trial results.
    • To demonstrate how quantitative interrelations of these variables can guide the planning and interpretation of cancer therapeutic trials.
    • To identify key factors contributing to chemotherapeutic failure in various cancers.

    Main Methods:

    Related Experiment Videos

  • Analysis of quantitative data relating staging, dose response, and tumor regrowth rates in experimental cancer models.
  • Integration of these variables to guide the design and interpretation of chemotherapy trials.
  • Evaluation of the impact of surgery followed by chemotherapy on metastatic solid animal cancers.

    • Main Results:

    • Chemotherapy trial results cannot be directly extrapolated between different cancer types without accounting for staging, dose response, and tumor regrowth.
    • Drug-resistant tumor cell selection and overgrowth are identified as primary reasons for chemotherapeutic failure in initially responsive cancers.
    • Combined surgery and chemotherapy improves cure rates in studied metastatic solid animal cancers.
    • Treatment failure occurs when the residual tumor burden post-surgery is too high for current chemotherapy regimens.

    Conclusions:

    • Accurate extrapolation of chemotherapy trial data necessitates quantitative corrections for biological differences between cancers.
    • Addressing drug resistance mechanisms and optimizing the timing and combination of surgery and chemotherapy are critical for improving cancer treatment outcomes.
    • The effectiveness of combined modality treatment is limited by the initial tumor burden and the efficacy of available chemotherapeutic agents.